| 6.285 -0.295 (-4.48%) | 04-25 15:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.99 |
1-year : | 16.65 |
| Resists | First : | 11.12 |
Second : | 14.26 |
| Pivot price | 7.36 |
|||
| Supports | First : | 6.05 |
Second : | 5.03 |
| MAs | MA(5) : | 6.65 |
MA(20) : | 8.11 |
| MA(100) : | 12.25 |
MA(250) : | 14.06 |
|
| MACD | MACD : | -1.6  |
Signal : | -1.6 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 11.7 |
| RSI | RSI(14): 22 |
|||
| 52-week | High : | 21.42 | Low : | 6.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VERV ] has closed above bottom band by 14.2%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.93 - 6.97 | 6.97 - 7.02 |
| Low: | 6.42 - 6.46 | 6.46 - 6.51 |
| Close: | 6.5 - 6.57 | 6.57 - 6.65 |
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Verve (VERV) Up on Gene Editing Collaboration With Vertex - Yahoo Movies UK
Sun, 21 Apr 2024
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ... - AccessWire
Sun, 21 Apr 2024
Verve Therapeutics, Inc. (NASDAQ:VERV) Stock Holdings Increased by Sumitomo Mitsui Trust Holdings Inc. - MarketBeat
Sat, 20 Apr 2024
Federated Hermes Inc. Buys 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Wed, 03 Apr 2024
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls - Yahoo Finance
Tue, 02 Apr 2024
Verve stock drops after setback for lead asset (NASDAQ:VERV) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 6.688e+007 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 12,520 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1767e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 48.7 % |
| Return on Equity (ttm) | -19.5 % |
| Qtrly Rev. Growth | 1.176e+007 % |
| Gross Profit (p.s.) | 240.17 |
| Sales Per Share | -20.46 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -150 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.31 |
| Price to Cash Flow | 1.45 |
| Dividend | 0 |
| Forward Dividend | 1.536e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|